Buffington Mohr McNeal trimmed its stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.8% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 26,731 shares of the medical research company's stock after selling 491 shares during the period. Thermo Fisher Scientific accounts for approximately 2.3% of Buffington Mohr McNeal's holdings, making the stock its 15th largest position. Buffington Mohr McNeal's holdings in Thermo Fisher Scientific were worth $13,906,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Nilsine Partners LLC lifted its stake in shares of Thermo Fisher Scientific by 4.6% during the 4th quarter. Nilsine Partners LLC now owns 10,665 shares of the medical research company's stock valued at $5,548,000 after buying an additional 473 shares in the last quarter. Foundations Investment Advisors LLC raised its stake in Thermo Fisher Scientific by 32.1% during the 4th quarter. Foundations Investment Advisors LLC now owns 1,513 shares of the medical research company's stock valued at $787,000 after purchasing an additional 368 shares during the period. Parsons Capital Management Inc. RI boosted its stake in Thermo Fisher Scientific by 18.5% in the 4th quarter. Parsons Capital Management Inc. RI now owns 36,190 shares of the medical research company's stock worth $18,827,000 after purchasing an additional 5,643 shares during the period. James Hambro & Partners LLP grew its holdings in Thermo Fisher Scientific by 6.1% during the 4th quarter. James Hambro & Partners LLP now owns 222,204 shares of the medical research company's stock valued at $115,606,000 after buying an additional 12,751 shares in the last quarter. Finally, Pacer Advisors Inc. lifted its holdings in shares of Thermo Fisher Scientific by 9.1% in the fourth quarter. Pacer Advisors Inc. now owns 31,559 shares of the medical research company's stock worth $16,418,000 after buying an additional 2,642 shares in the last quarter. 89.23% of the stock is currently owned by hedge funds and other institutional investors.
Analysts Set New Price Targets
TMO has been the topic of several research analyst reports. Robert W. Baird decreased their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an "outperform" rating on the stock in a research note on Thursday, October 24th. Scotiabank assumed coverage on Thermo Fisher Scientific in a research note on Monday, December 23rd. They issued a "sector perform" rating and a $605.00 price objective on the stock. Bernstein Bank increased their target price on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a "market perform" rating in a research report on Tuesday, October 22nd. Stifel Nicolaus decreased their price target on shares of Thermo Fisher Scientific from $680.00 to $665.00 and set a "buy" rating on the stock in a research note on Thursday, October 24th. Finally, Stephens began coverage on shares of Thermo Fisher Scientific in a report on Tuesday, October 1st. They issued an "overweight" rating and a $680.00 target price on the stock. Four investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $648.95.
Read Our Latest Stock Analysis on TMO
Insiders Place Their Bets
In related news, CEO Marc N. Casper sold 10,000 shares of the firm's stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the transaction, the chief executive officer now owns 111,192 shares of the company's stock, valued at $58,960,669.92. This trade represents a 8.25 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last quarter, insiders have sold 34,850 shares of company stock valued at $19,123,197. Insiders own 0.34% of the company's stock.
Thermo Fisher Scientific Stock Down 0.0 %
Shares of NYSE:TMO traded down $0.23 during trading on Tuesday, reaching $583.41. The stock had a trading volume of 1,241,409 shares, compared to its average volume of 1,939,809. The company has a market capitalization of $223.15 billion, a P/E ratio of 36.59, a PEG ratio of 3.82 and a beta of 0.76. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The firm's 50-day simple moving average is $535.24 and its 200 day simple moving average is $570.10.
Thermo Fisher Scientific Announces Dividend
The firm also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Stockholders of record on Friday, December 13th were paid a dividend of $0.39 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific's payout ratio is 9.78%.
Thermo Fisher Scientific announced that its Board of Directors has approved a share repurchase program on Friday, November 15th that authorizes the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to buy up to 2% of its stock through open market purchases. Stock repurchase programs are typically a sign that the company's leadership believes its shares are undervalued.
Thermo Fisher Scientific Profile
(
Free Report)
Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
Further Reading
Before you consider Thermo Fisher Scientific, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Thermo Fisher Scientific wasn't on the list.
While Thermo Fisher Scientific currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
